## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours ner resnonse.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     McCarthy Sean A.					2. Issuer Name and Ticker or Trading Symbol  CytomX Therapeutics, Inc. [ CTMX ]							ck all applica Director	ıble)	erson(s) to Iss	wner
(Last) (First) (Middle) C/O CYTOMX THERAPEUTICS, INC. 151 OYSTER POINT BLVD., STE. 400					3. Date of Earliest Transaction (Month/Day/Year) 08/10/2022						x	below)	give title CEC	Other ( below)	specily
(Street) SOUTH S. FRANCIS	( 'A	. 9	94080	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					Line)	Individual or Joint/Group Filing (Check Applicable ne)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Sta		Zip)												
		Tak	ole I - Non-D					<del>-</del>				1			
Date				action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Inst	Transaction Disposed Of (D) (Instr. 3, 4 a			5. Amount Securities Beneficial Owned Fo Reported	Form: (D) or	rm: Direct	. Nature of ndirect seneficial ownership lnstr. 4)		
							Code V	Amount	(A) or (D)	Price	Transactio			(111511.4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	ivative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) if any		Code	saction (Instr.	Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)	
				Code	· v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	(Instr. 4)		(3)	
Stock Option (Right to Buy)	\$1.59	08/10/2022		A		450,000		(1)	08/09/2032	Common Stock	450,000	\$0.00	450,000	D	
Performance Stock Units (PSUs)	(2)	08/10/2022		A		75,000		(2)	(2)	Common Stock	75,000	\$0.00	75,000	D	

## **Explanation of Responses:**

- 1. 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 10, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
- 2. Each Performance Stock Unit ("PSU") represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2023 and 50% of the PSUs vest upon achievement of a certain performance-based milestone by 12/31/2024.

/s/ Lloyd Rowland, as Attorney-08/12/2022 in-Fact for Sean A. McCarthy

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.